{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:05:33Z","timestamp":1787162733929,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402318"],"award-info":[{"award-number":["82402318"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472015"],"award-info":[{"award-number":["82472015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373082"],"award-info":[{"award-number":["82373082"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303583"],"award-info":[{"award-number":["82303583"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Hospitals Authority\u2019s Ascent Plan","award":["DFL20241103"],"award-info":[{"award-number":["DFL20241103"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["No. 2022-2Z-2155"],"award-info":[{"award-number":["No. 2022-2Z-2155"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2024-2-2153"],"award-info":[{"award-number":["2024-2-2153"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2024-1-1023, 2022-02-1023"],"award-info":[{"award-number":["2024-1-1023, 2022-02-1023"]}]},{"name":"Beijing Research Ward Excellence Program","award":["BRWEP2024W032150102"],"award-info":[{"award-number":["BRWEP2024W032150102"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"crossref","award":["2022YFC2409405"],"award-info":[{"award-number":["2022YFC2409405"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Natural Science Foundation","award":["L222020, L248048"],"award-info":[{"award-number":["L222020, L248048"]}]},{"name":"Science Foundation of Peking University Cancer Hospital","award":["2022-05, 2022-11"],"award-info":[{"award-number":["2022-05, 2022-11"]}]},{"DOI":"10.13039\/501100018538","name":"National Ten-thousand Talent Program","doi-asserted-by":"crossref","award":["National Ten-thousand Talent Program"],"award-info":[{"award-number":["National Ten-thousand Talent Program"]}],"id":[{"id":"10.13039\/501100018538","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science Foundation of Peking University Cancer Hospital","award":["PY202311"],"award-info":[{"award-number":["PY202311"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00259-025-07115-3","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T23:17:26Z","timestamp":1738797446000},"page":"2343-2354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer"],"prefix":"10.1007","volume":"52","author":[{"given":"Xin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8619-7550","authenticated-orcid":false,"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"7115_CR1","unstructured":"NCCN Clinical Practice Guidelines in. Non-Small Cell Lung Cancer. Version 6.2021. NCCNorg. 2021."},{"key":"7115_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","volume":"18","author":"MJ Grant","year":"2021","unstructured":"Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021;18:625\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00520-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"7115_CR3","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/s1470-2045(20)30453-8","volume":"21","author":"M Provencio","year":"2020","unstructured":"Provencio M, Nadal E, Insa A, Garc\u00eda-Campelo MR, Casal-Rubio J, D\u00f3mine M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413\u201322. https:\/\/doi.org\/10.1016\/s1470-2045(20)30453-8.","journal-title":"Lancet Oncol"},{"key":"7115_CR4","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/jco.21.00276","volume":"39","author":"SI Rothschild","year":"2021","unstructured":"Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, et al. SAKK 16\/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in patients with Stage IIIA(N2) non-small-cell Lung Cancer-A Multicenter single-arm phase II trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2021;39:2872\u201380. https:\/\/doi.org\/10.1200\/jco.21.00276.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"7115_CR5","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/s1470-2045(20)30140-6","volume":"21","author":"CA Shu","year":"2020","unstructured":"Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:786\u201395. https:\/\/doi.org\/10.1016\/s1470-2045(20)30140-6.","journal-title":"Lancet Oncol"},{"key":"7115_CR6","doi-asserted-by":"publisher","first-page":"760737","DOI":"10.3389\/fimmu.2021.760737","volume":"12","author":"YD Yan","year":"2021","unstructured":"Yan YD, Cui JJ, Fu J, Su YJ, Chen XY, Gu ZC, et al. A Network comparison on Safety Profiling of Immune checkpoint inhibitors in Advanced Lung Cancer. Front Immunol. 2021;12:760737. https:\/\/doi.org\/10.3389\/fimmu.2021.760737.","journal-title":"Front Immunol"},{"key":"7115_CR7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7.","journal-title":"Lancet"},{"key":"7115_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrd2290","volume":"7","author":"JK Willmann","year":"2008","unstructured":"Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008;7:591\u2013607. https:\/\/doi.org\/10.1038\/nrd2290.","journal-title":"Nat Rev Drug Discov"},{"key":"7115_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1470-2045(10)70009-7","volume":"11","author":"H Kobayashi","year":"2010","unstructured":"Kobayashi H, Longmire MR, Ogawa M, Choyke PL, Kawamoto S. Multiplexed imaging in cancer diagnosis: applications and future advances. Lancet Oncol. 2010;11:589\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70009-7.","journal-title":"Lancet Oncol"},{"key":"7115_CR10","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0255-8.","journal-title":"Nat Med"},{"key":"7115_CR11","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","volume":"9","author":"AN Niemeijer","year":"2018","unstructured":"Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen G, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9:4664. https:\/\/doi.org\/10.1038\/s41467-018-07131-y.","journal-title":"Nat Commun"},{"key":"7115_CR12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.121.262045","volume":"63","author":"X Zhou","year":"2022","unstructured":"Zhou X, Jiang J, Yang X, Liu T, Ding J, Nimmagadda S, et al. First-in-humans evaluation of a PD-L1-Binding peptide PET Radiotracer in Non-small Cell Lung Cancer patients. J Nucl Med. 2022;63:536\u201342. https:\/\/doi.org\/10.2967\/jnumed.121.262045.","journal-title":"J Nucl Med"},{"key":"7115_CR13","doi-asserted-by":"publisher","first-page":"101425","DOI":"10.1016\/j.smim.2020.101425","volume":"52","author":"ER Verhaar","year":"2021","unstructured":"Verhaar ER, Woodham AW, Ploegh HL. Nanobodies in cancer. Semin Immunol. 2021;52:101425. https:\/\/doi.org\/10.1016\/j.smim.2020.101425.","journal-title":"Semin Immunol"},{"key":"7115_CR14","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.2967\/jnumed.122.263907","volume":"63","author":"W Wei","year":"2022","unstructured":"Wei W, Younis MH, Lan X, Liu J, Cai W. Single-domain antibody theranostics on the Horizon. J Nucl Med. 2022;63:1475\u20139. https:\/\/doi.org\/10.2967\/jnumed.122.263907.","journal-title":"J Nucl Med"},{"key":"7115_CR15","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","volume":"10","author":"EY Yang","year":"2020","unstructured":"Yang EY, Shah K, Nanobodies. Next Generation of Cancer Diagnostics and therapeutics. Front Oncol. 2020;10:1182. https:\/\/doi.org\/10.3389\/fonc.2020.01182.","journal-title":"Front Oncol"},{"key":"7115_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2967\/jnumed.119.226712","volume":"61","author":"G Lv","year":"2020","unstructured":"Lv G, Sun X, Qiu L, Sun Y, Li K, Liu Q, et al. PET imaging of Tumor PD-L1 expression with a highly specific nonblocking single-domain antibody. J Nucl Med. 2020;61:117\u201322. https:\/\/doi.org\/10.2967\/jnumed.119.226712.","journal-title":"J Nucl Med"},{"key":"7115_CR17","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1007\/s00259-023-06373-3","volume":"50","author":"X Ma","year":"2023","unstructured":"Ma X, Zhou X, Hu B, Li X, Yao M, Li L, et al. Preclinical evaluation and pilot clinical study of [(68)Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging. Eur J Nucl Med Mol Imaging. 2023;50:3838\u201350. https:\/\/doi.org\/10.1007\/s00259-023-06373-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"7115_CR18","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):S122\u201350. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med"},{"key":"7115_CR19","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2967\/jnumed.121.262473","volume":"63","author":"J Smit","year":"2022","unstructured":"Smit J, Borm FJ, Niemeijer AN, Huisman MC, Hoekstra OS, Boellaard R, et al. PD-L1 PET\/CT Imaging with Radiolabeled Durvalumab in patients with Advanced-Stage Non-small Cell Lung Cancer. J Nucl Med. 2022;63:686\u201393. https:\/\/doi.org\/10.2967\/jnumed.121.262473.","journal-title":"J Nucl Med"},{"key":"7115_CR20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262368","author":"PH Nienhuis","year":"2021","unstructured":"Nienhuis PH, Antunes IF, Glaudemans A, Jalving M, Leung D, Noordzij W, et al. (18)F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study. J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.121.262368.","journal-title":"J Nucl Med"},{"key":"7115_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.annonc.2021.10.213","volume":"33","author":"IC Kok","year":"2022","unstructured":"Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, et al. (89)Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. Ann Oncol. 2022;33:80\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2021.10.213.","journal-title":"Ann Oncol"},{"key":"7115_CR22","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2967\/jnumed.118.224170","volume":"60","author":"Y Xing","year":"2019","unstructured":"Xing Y, Chand G, Liu C, Cook GJR, O\u2019Doherty J, Zhao L, et al. Early phase I study of a (99m)Tc-labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT\/CT assessment of PD-L1 expression in non-small cell lung cancer. J Nucl Med. 2019;60:1213\u201320. https:\/\/doi.org\/10.2967\/jnumed.118.224170.","journal-title":"J Nucl Med"},{"key":"7115_CR23","doi-asserted-by":"publisher","unstructured":"Zhang Y, Cao M, Wu Y, Malih S, Xu D, Yang E, et al. Preclinical development of novel PD-L1 tracers and first-in-human study of [(68)Ga]Ga-NOTA-RW102 in patients with lung cancers. J Immunother Cancer. 2024;12. https:\/\/doi.org\/10.1136\/jitc-2024-008794.","DOI":"10.1136\/jitc-2024-008794"},{"key":"7115_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00259-017-3924-9","volume":"45","author":"T Derlin","year":"2018","unstructured":"Derlin T, Schmuck S, Juhl C, Z\u00f6rgiebel J, Schneefeld SM, Walte ACA, et al. PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:913\u201322. https:\/\/doi.org\/10.1007\/s00259-017-3924-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7115_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/978-1-4939-8648-4_26","volume-title":"Antibody Engineering: methods and protocols","author":"M Crauwels","year":"2018","unstructured":"Crauwels M, Massa S, Martin C, Betti C, Ballet S, Devoogdt N, et al. Site-specific Radioactive labeling of Nanobodies. In: Nevoltris D, Chames P, editors. Antibody Engineering: methods and protocols. New York, NY: Springer New York; 2018. pp. 505\u201340."},{"key":"7115_CR26","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-020-04711-3","volume":"47","author":"X Tao","year":"2020","unstructured":"Tao X, Li N, Wu N, He J, Ying J, Gao S, et al. The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47:1209\u201319. https:\/\/doi.org\/10.1007\/s00259-020-04711-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7115_CR27","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.annonc.2024.06.014","volume":"35","author":"A Di Federico","year":"2024","unstructured":"Di Federico A, Alden SL, Smithy JW, Ricciuti B, Alessi JV, Wang X, et al. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Ann Oncol. 2024;35:902\u201313. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.014.","journal-title":"Ann Oncol"},{"key":"7115_CR28","doi-asserted-by":"publisher","unstructured":"Wu Y, Xu D, Gu Y, Li G, Wang H, Cao M, et al. Assessment of PD-L1 expression in Non-small Cell Lung cancers using [(68)Ga]Ga-DOTA-WL12 PET\/CT. Small Methods. 2024;e2400358. https:\/\/doi.org\/10.1002\/smtd.202400358.","DOI":"10.1002\/smtd.202400358"},{"key":"7115_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","volume":"15","author":"WD Travis","year":"2020","unstructured":"Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, et al. IASLC Multidisciplinary recommendations for Pathologic Assessment of Lung Cancer resection specimens after neoadjuvant therapy. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2020;15:709\u201340. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.005.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"key":"7115_CR30","doi-asserted-by":"crossref","unstructured":"Miedema IHC, Pouw JEE, Kwakman A, Zwezerijnen GJC, Huisman MC, Timmer FEF et al. Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by <\u2009sup\u2009>\u200918\u2009F-BMS-986192 PET: pooled analysis of data from four solid tumor types. J Immunother Cancer. 2024;12.","DOI":"10.1136\/jitc-2024-008899"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07115-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07115-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07115-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T06:17:55Z","timestamp":1748413075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07115-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["7115"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07115-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of Peking University Cancer Hospital (2021KT111), oral and written informed consent was obtained from all participants. This study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interests exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}